This session explores complex coronary challenges and anatomical anomalies encountered in clinical practice. Topics include management of thrombus showers from unexpected culprits, ultra-low contrast angioplasty in mesenteric ischemia, advanced bifurcation PCI techniques with IVUS guidance, and troubleshooting difficult stent delivery scenarios in calcified lesions and challenging...

Focus on the evolving role of drug-coated balloons (DCB) in complex PCI, extending their use beyond traditional indications to challenging coronary lesions and high-risk patient populations. This session reviews clinical data from the SCAAR Prevail registry and discusses the evidence journey supporting broader advocacy for DCB...

Addressing current challenges in complex coronary interventions, this session covers management strategies for CHIP patients, advanced techniques for highly calcified lesions, and principles for mechanical circulatory support application in high-risk PCI scenarios. It offers practical insights and case-based discussions to optimize safety and efficacy in contemporary...

A 61-year-old man with a history of 2-vessel coronary artery stenting, hypertension and type-2 diabetes mellitus was admitted 5 times within September 2017 and November 2018 for recurrent angina CCS class III-IV refractory to therapy with nitrates, b-blockers and ranolazine in maximally tolerated doses...

Mirvat Alasnag reviews the OPTIMUM trial, presented by David E. Kandzari, which reports outcomes in a subset of patients who are increasingly seen in modern day catheterization laboratories. It is noteworthy that 1 in 5 patients with left main or multivessel disease are considered surgically ineligible.

Panos Xaplanteris provides his take on WATCH-TAVR results which were presented by Samir R. Kapadia at TCT Congress 2023.

Safety and Efficacy of Left Atrial Appendage Occlusion at the Time of Transcatheter Aortic Valve Replacement - The WATCH TAVR Trial

Paris, France, 22 May 2019. Identification and management of patients at high bleeding risk (HBR) undergoing percutaneous coronary intervention (PCI) is of major importance, but a lack of standardisation in defining this population limits trial design, data interpretation, and clinical decision-making.

Paris, France, 24 May 2019. A total of 11,206 participants from over 120 different countries were present at the 30th edition of EuroPCR. An additional 4,700 online learners connected to watch a selection of sessions that were made available both live and on replay via PCR...

The results of the SCOPE I trial were presented at TCT 2019 in San Francisco by Jonas Lanz, Bern University Hospital. Read the analysis by Fabien Praz.

Kalaivani Mahadevan provides her take on the five-year outcomes of the FAME 3 trial presented by William F. Fearon at ACC.25 in Chicago.

Daniele Giacoppo analyses the main results of the FLAVOUR trial which were presented by Bon-Kwon Koo, from Seoul National University Hospital, South Korea at the American College of Cardiology 2022.